Smart App Support After Stroke or Mini-Stroke Discharge
Tests a WeChat-based smart system for adults after an ischemic stroke or TIA.
Plain-language title generated from the registry record
Registry title: Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack With an Intelligent Management System
Key facts
- Where
- Beijing and Shihezi, ChinaSee the 3 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who recently had an ischemic stroke or a transient ischemic attack (TIA). They also need high blood pressure or diabetes and must be able to use a smartphone.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Acute ischemic stroke or transient ischemic attack. No more than 14 days between the start of symptoms and joining the trial.
- Earlier treatment
- Not in other stroke-related care improvement projects or clinical trials.
Main reasons for not taking part
- Already in another stroke-related care improvement project or clinical trial
- The patient or family refuses to sign the consent form
- Pregnant or breastfeeding women
Read by machine on 12 November 2026.
Where in China
- Beijing Tiantan HospitalBeijing, ChinaContact: Zhiyuan FengTaking people
- Beijing Tsinghua Changgung HospitalBeijing, ChinaContact: Zhiyuan Feng, MDNo longer taking part
- The First Affiliated Hospital of Shihezi UniversityShihezi, ChinaContact: Zhiyuan Feng, MDNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Beijing Tiantan Hospital
- Trial code
- NCT06783049
- Record updated
- 21 January 2026
- Original description
The purpose of this study is to develop a digital health-based intelligent management system for the secondary prevention of ischemic stroke and to evaluate its effectiveness through a multicenter randomized controlled trial, assessing its health economic value.Read full original descriptionShow less
Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack With an Intelligent System
The purpose of this study is to develop a digital health-based intelligent management system for the secondary prevention of ischemic stroke and to evaluate its effectiveness through a multicenter randomized controlled trial, assessing its health economic value.
Participants will receive usual care after discharge (control group) or be managed with a WeChat-based intelligent management system after discharge (intervention group).
At one year, all patients will undergo face-to-face follow-up to assess clinical events, medication adherence, and the achievement of target risk factor levels.
Inclusion: Age ≥ 18 years; Patients diagnosed with acute ischemic stroke or transient ischemic attack; Time from onset to enrollment ≤ 14 days; Presence of at least one modifiable risk factor (hypertension, diabetes); Ability to independently use a smartphone to complete system tasks upon discharge, or with the assistance of family members; Signed informed consent by the patient or their family members.
Exclusion: Patients already enrolled in other stroke-related healthcare quality improvement projects or clinical trials; Patients or family members who refuse to sign the informed consent form; Pregnant or breastfeeding women.